Safety and specific activity of the recombinant SARS-CoV-2 allergen (“CoronaDerm-PS”) based on phase I–II clinical trial results

Tikhon V. Savin; Савин Тихон Валерьевич; A. M. Milichkina; Миличкина А. М.; A. A. Krasnov; Краснов А. А.; R. N. Kuznetsova; Кузнецова Р. Н.; E. E. Shchederkina; Щедеркина Е. Е.; A. V. Svarval; Сварваль А. В.; A. А. Sharova; Шарова А. А.; D. E. Reingardt; Рейнгардт Д. Э.; Yu. V. Ostankova; Останкова Ю. В.; A. V. Gubanova; Губанова А. В.; O. A. Petrova; Петрова О. А.; O. B. Zhimbaeva; Жимбаева О. Б.; A. P. Razumovskaya; Разумовская А. П.; I. V. Drozd; Дрозд И. В.; A. А. Rubinstein; Рубинштейн А. А.; A. S. Trulev; Трулев А. С.; I. V. Kudryavtsev; Кудрявцев И. В.; A. A. Riabchenkova; Рябченкова А. А.; E. L. Chirak; Чирак Е. Л.; E. R. Chirak; Чирак Е. Р.; A. I. Saenko; Саенко А. И.; V. V. Kopat; Копать В. В.; I. V. Dukhovlinov; Духовлинов И. В.; A. S. Simbirtsev; Симбирцев А. С.; A. A. Totolian; Тотолян А. А.

doi:10.15789/2220-7619-SAS-17790

Safety and specific activity of the recombinant SARS-CoV-2 allergen (“CoronaDerm-PS”) based on phase I–II clinical trial results

作者: Savin T.V.¹^,2, Milichkina A.M.¹, Krasnov A.A.¹, Kuznetsova R.N.³^,2, Shchederkina E.E.¹, Svarval A.V.¹, Sharova A.А.¹, Reingardt D.E.¹, Ostankova Y.V.¹, Gubanova A.V.¹, Petrova O.A.¹^,2, Zhimbaeva O.B.¹, Razumovskaya A.P.¹, Drozd I.V.¹, Rubinstein A.А.⁴, Trulev A.S.⁴, Kudryavtsev I.V.²^,4, Riabchenkova A.A.⁵, Chirak E.L.⁵, Chirak E.R.⁵, Saenko A.I.⁵, Kopat V.V.⁵, Dukhovlinov I.V.⁵, Simbirtsev A.S.¹^,2, Totolian A.A.¹^,2
隶属关系:
1. St. Petersburg Pasteur Institute
2. Pavlov First St. Petersburg State Medical University
3. St. Petersburg Pasteur Institute, St. Petersburg
4. Institute of Experimental Medicine
5. LLC “ATG Service-Gene”
期: 卷 14, 编号 5 (2024)
页面: 900-916
栏目: ORIGINAL ARTICLES
URL: https://journal-vniispk.ru/2220-7619/article/view/284794
DOI: https://doi.org/10.15789/2220-7619-SAS-17790
ID: 284794

如何引用文章

全文:

详细
全文:
作者简介
参考
补充文件
统计

详细

The evaluation of cellular immunity to SARS-CoV-2 is a critical tool for assessing vaccination efficacy and development of post-infectious immunity. According to available studies, virus-specific T cells persist longer than antigen-specific antibodies and play a pivotal role in the effective virus elimination from human body. Current methodologies for assessing virus-specific T cells are mostly based on flow cytometry, which require specialized laboratory equipment and highly trained personnel. An alternative approach involves a skin test conducted to assess delayed-type hypersensitivity (DTH) reactions. For this, there has been developed the “CoronaDerm-PS” substance, a sterile isotonic solution for intradermal administration, containing a recombinant hybrid protein that incorporates regions of SARS-CoV-2 structural proteins S, M, N, and E, produced by a genetically modified E. coli BL21 strain cell culture. Following preclinical studies that demonstrated the safety of the above-noted medication, Phase I and Phase II clinical trials were initiated to evaluate safety and specific activity of “CoronaDerm-PS” in apparently healthy volunteers with SARS-CoV-2 post-vaccination and post-infection immunity. In Phase I clinical trial with COVID-19 unexposed or vaccinated volunteers, the data were obtained demonstrating the safety and good tolerability of the medication, thus enabling the progression to Phase II. The Phase II results provided additional evidence on the preparation’s safety in individuals with SARS-CoV-2 post-vaccination and post-infection immunity, as assessed by clinical and laboratory data. No serious adverse events were observed during the study, and in 93.5% cases, adverse events required no therapeutic or diagnostic intervention. To assess the specific activity of the preparation, the skin test data were compared with the IFNγ production stimulation index for CD4⁺ T lymphocytes assessed by flow cytometry. The ROC analysis revealed sensitivity magnitude ranging from 76.6% to 84%, and specificity level ranging from 80% to 87.5%. Based on ROC analysis results, “CoronaDerm-PS” can be an informative diagnostic tool (AUC = 0.795), demonstrating high sensitivity (79.8%) and specificity (80.8%), with consistent results across different volunteer cohorts. Analyzing the collected data suggests that “CoronaDerm-PS” is a robust alternative to laboratory methods for evaluating SARS-CoV-2-specific T-cell immunity, with high sensitivity and specificity, suitable for large-scale screening.

关键词

SARS-CoV-2, COVID-19, coronavirus antigen Cord_PS, CD4+ T cells, CD8+ T cells, IFNγ, T cell immune response, “CoronaDerm-PS”

全文:

##article.viewOnOriginalSite##

作者简介

Tikhon Savin

St. Petersburg Pasteur Institute; Pavlov First St. Petersburg State Medical University

编辑信件的主要联系方式.
Email: savin@pasteurorg.ru

Allergologist-Immunologist, Senior Laboratory Assistant, Department of Immunology

俄罗斯联邦, St. Petersburg; St. Petersburg

A. Milichkina

St. Petersburg Pasteur Institute

用户名
密码
记住我

忘记您的密码?	注册

用户名
密码
记住我

忘记您的密码?	注册

Safety and specific activity of the recombinant SARS-CoV-2 allergen (“CoronaDerm-PS”) based on phase I–II clinical trial results

全文:

详细

关键词

全文:

作者简介

参考

补充文件